04/07/2017 17:00:14

NeuroSearch and Saniona enter into agreement on transfer of rights

Related content
21 Mar - 
Report on Annual General Meeting of NeuroSearch A/S
07 Mar - 
Report pursuant to section 28a of the Danish Act on Sec..
27 Feb - 
Notice convening the Annual General Meeting of NeuroSea..
Related debate
05 Jul - 
Er det kursen på Neurosearch eller Saniona, som vil sti..
04 Jul - 
Lyder kryptisk! Hvad bygger du det på?
04 Jul - 
Kursen vil stige. Taastrup

Company announcement

4 July 2017

NeuroSearch announces that it has sold to Saniona A/S its remaining rights in the preclinical and clinical assets which NeuroSearch divested to Saniona during the period 2012-2016. In full and final settlement of NeuroSearch’s remaining rights in the divested programs, NeuroSearch will receive from Saniona a one-time cash payment of DKK 5.5 million. Furthermore, Saniona will fully assume NeuroSearch’s royalty obligations to third parties regarding potential net sales of products, including NeuroSearch’s royalty payment obligations to Boehringer Ingelheim on tesofensine and to GlaxoSmithKline on NS2359.

In August 2012, NeuroSearch sold its technology platform including patents and data in relation to 15 preclinical and clinical programs to Saniona. In October 2014, the rights to NeuroSearch’s clinical development compounds, tesofensine and NS2359, were divested to Saniona. In May 2016, NeuroSearch divested its rights to the remaining projects and compounds, including the clinical development compounds ACR325 and ACR343, to Saniona.

Of the DKK 5.5 million received, NeuroSearch will pay DKK 0.4 million in total to Boehringer Ingelheim and GlaxoSmithKline. The remaining DKK 5.1 million will add DKK 2.2 million to our operating income, and the remaining DKK 2.9 million will be added to discontinued operations.

NeuroSearch still has potential milestone payments from TEVA totalling up to DKK 55 million if Huntexil® is granted market approval.

The conclusion of this agreement follows NeuroSearch’s announced strategy to dispose of all remaining assets in the best possible way.

Outlook for 2017

For 2017, NeuroSearch now expects an operating loss in the range of DKK 2.3-3.3 million, against previously DKK 4.5-5.5 million. The outlook primarily includes costs for the continuing efforts to dispose of the Company’s assets, maintaining the Company’s stock exchange listing and maintaining its day-to-day operations. The outlook does not include any further income from the possible sale of Company assets or other potential income from the Company's agreement with Teva.

Contact

Allan Andersen, CEO, mobile +45 4016 3864.

About NeuroSearch

NeuroSearch A/S (NEUR) is listed on Nasdaq Copenhagen A/S.

 

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Majedie Asset Management Ltd : Form 8.3 - TESCO PLC

18/08/2017 15:36:47
FORM 8.3   PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code")   1.         KEY INFORMATION   (a) Full name of discloser: ..

Alliance Trust PLC : Net Asset Value(s)

18/08/2017 12:56:57
ALLIANCE TRUST PLC                                    At the close of business on Thursday 17 August 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 761.7p -       including income, 771.7p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inc..

Form 8.5 (EPT/RI) - Tesco plc

18/08/2017 08:17:38
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY 1.         KEY INFORMATION (a) Name of exempt principal trader:   Investec Bank plc   (b) Name of offeror/offeree in relation to whose relevant se..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in B Communications Ltd. of Class Action Lawsuit and Upcoming Deadline – BCOM
2
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tableau Software, Inc. of Class Action Lawsuit and Upcoming Deadline – DATA
3
AIR FRANCE - KLM: Availability of the prospectus relating to the capital increases reserved to China Eastern Airlines and Delta Air Lines
4
85th National Convention of the Military Order of the Purple Heart in Dallas, Texas Concludes with Election of Patriot Neil Van Ess as National Commander
5
Carahsoft Listed on the Inc. 5000 List for the Tenth Consecutive Year

Related stock quotes

NeuroSearch A/S 3.60 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 August 2017 04:47:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20170808.1 - EUROWEB1 - 2017-08-19 05:47:41 - 2017-08-19 04:47:41 - 1000 - Website: OKAY